| Document |
Document Title |
|
WO2006120628B1 |
This invention is related to the preparation of alkyl or alcoxyalkyl-a-cyanoacrylates in monomeric form by depolymerisation of the corresponding poly(alkyl-a-cyanoacrylates) or poly(alcoxyalkyl-a-cyanoacrylates) (PCA). The PCA's are obta...
|
|
WO/2007/031534A1 |
The invention relates to a method for the production of β-aminopropionic acid derivatives by reaction of a primary or secondary amine with an acrylic acid derivative, wherein (i) a first primary or secondary amine is provided as amine o...
|
|
WO/2007/023788A1 |
Disclosed is a benzonitrile derivative which is useful as a production intermediate for benzylamine derivative represented by the general formula (5) below and a secondary amine derivative represented by the general formula (9) below. Al...
|
|
WO/2007/020381A2 |
A process for the preparation of a compound of formula (I) wherein: R is an alkynyl group; R1 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, phenyl and phenylalkyl, it being possible in turn for all of the receding groups to c...
|
|
WO/2007/018221A1 |
The invention provides an easy and simple process for the production of 2-hydroxy esters from cyanohydrins, specifically, a process for the production of 2-hydroxy esters represented by the general formula (1) (exclusive of ethyl 2-hydro...
|
|
WO/2007/017431A1 |
In a process for producing catalyst mouldings whose active mass is a multi-element oxide, a finely divided precursor mixture is moulded, with the admixture of boron nitride, to produce the desired geometry, then thermally treated.
|
|
WO/2007/017754A2 |
The present invention is directed to a new class of benzonitriles and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stim...
|
|
WO/2007/017267A2 |
Compounds of formula (I): are inhibitors of bacterial phenylalanyl t-RNA synthetase and are of use in treating bacterial infections.
|
|
WO/2007/017088A1 |
The invention relates to compounds of the general formula (I), wherein R1, R2, R3, R4, R5, R6, R7, Ar1 X, Y, a and b are as defined in claim 1 , and, if appropriate, enantiomers thereof. The active compounds have advantageous pesticidal ...
|
|
WO/2007/014899A1 |
Dicyano alkanoic acid amides of formula (I), wherein R1 is H, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, or haloalkynyl; R2 is H, CN, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl, halocycloalkyl, alkoxy,...
|
|
WO/2007/014607A1 |
The invention relates to compounds of formula (I), wherein R, X, R 1, R2,R3, R4 and R5 have the significances specified in claim 1, wherein said compounds are embodied in the form of CHK1- CHK2- and SGK kinase inhibitors and can be used,...
|
|
WO/2007/013694A1 |
A compound represented by the general formula (I): (I) wherein each symbol is as defined in the description. The compound is excellent in the effect of decreasing the blood glucose level and the blood lipid level, and therefore is useful...
|
|
WO/2007/009921A1 |
Disclosed is a full catalyst comprising a) a supporting material selected among aluminum oxide, silicon dioxide, aluminum silicate, magnesium silicate, titanium dioxide, zirconium dioxide, thorium dioxide, silicon carbide, or mixtures th...
|
|
WO/2007/010519A1 |
A polymer matrix comprising active chromophoric groups and aromatic compounds selected from phenyls substituted with one or more substituents independently selected from: (i) halogens; (ii) C1-4alkyl esters of carboxylic acid or their am...
|
|
WO/2007/009389A2 |
The present invention provides compounds of formula (I), the preparation thereof and their use as peroxisome proliferator activated receptor-γ (PPAR-γ) agonist in the treatment of diabetes and diabetic complications.
|
|
WO/2007/007149A1 |
The present invention is directed to a new class of benzonitriles and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stim...
|
|
WO/2007/005531A2 |
Non-nucleoside inhibitors of HIV-I reverse transcriptase are described. Such inhibitors may be used as part of a combination therapy to treat HIV infection. Compounds described herein exhibit antiviral potency. In addition, compounds des...
|
|
WO/2007/002722A2 |
The invention is directed to processes for purifying the Anastrozole intermediate, 3,5-bis(2-cyanoisopropyl)toluene, processes for producing Anastrozole, processes for preparing Anastrozole pharmaceutical compositions, and Anastrozole an...
|
|
WO/2007/000294A1 |
Process for the preparation of 1-[cyano (phenyl) methyl] cyclohexanol compounds of general formula (I) in which R1 is hydrogen, (C1-4) alkyl or (C1-4) alkoxy, wherein a compound of general formula (II) in which R1 is as defined above, is...
|
|
WO/2007/002720A2 |
Reference markers and reference standards for the determination of impurities in Anastrozole are provided.
|
|
WO/2007/000250A1 |
The invention relates to a method for producing aryl or heteroaryl amines, ethers or thioethers (III) by cross-coupling primary or secondary amines, alcohols or thioalcohols (II) with substituted aryl or heteroaryl compounds (I) in the p...
|
|
WO/2006/138660A2 |
The invention relates to substituted adamantane compounds of formula (I), pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferati...
|
|
WO/2006/136910A1 |
The invention is directed to a process for producing the compound 4-(4- Hydroxy-1-methyl-pentyloxy)-2-trifluoromethyl-benzonitrile or a pharmaceutically acceptable salt thereof.
|
|
WO/2006/137195A1 |
The sulfonate catalyst represented by the following formula and a ketone compound are added to a solvent and the ingredients are mixed together in the presence of hydrogen. Thus, the ketone compound is hydrogenated to produce an opticall...
|
|
WO/2006/136135A2 |
The invention relates to a method for decarboxylating C-C cross-linking by reacting carboxylic salts with carbon electrophiles in the presence of transition metal compounds as catalysts. The method represents a decarboxylating cross-coup...
|
|
WO/2006/136521A1 |
A process is described for the preparation of escitalopram and the pharmaceutically acceptable salts thereof starting from 5-cyanophthalide by a process which provides an enantioselective enzymatic deacylation reaction of a complex of th...
|
|
WO/2006/133592A1 |
Compounds of formula (I) and their use as fragrance ingredients wherein R is selected from methyl, ethyl, propyl, isopropyl, methoxy and ethoxy; R' is hydrogen or methyl; and n is 0 or 1.
|
|
WO/2006/134040A1 |
The invention is concerned with novel anthranilic acid derivatives of formula (I) wherein R1 to R14, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compo...
|
|
WO/2006/133559A1 |
The instant invention relates to compounds of formula I, diagrammed below, wherein R3, E, D and Y are defined in the application, which are useful as reversible inhibitors of monoamine oxidase-B and/or monoamine oxidase-A, and therefore ...
|
|
WO/2006/133216A2 |
This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.
|
|
WO/2006/130196A2 |
A catalyst composition for the oxidation and ammoxidation of hydrocarbons comprising a plurality of silica sol particles with different average particle sizes, and a complex of metal catalytic oxides having the formula: (i) AaBbCcBidMoeO...
|
|
WO/2006/125778A1 |
The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful in the treatment, including prevention, of obesity, diabetes and a number of diseases or disorders associated therewith.
|
|
WO/2006/123767A1 |
Disclosed is a method for commercially producing a spiroaminopyrrolidone derivative as an intermediate for a quinolone antibacterial agent. Specifically disclosed is a method for producing a compound represented by the formula (2) below ...
|
|
WO/2006/123672A1 |
Disclosed is a method for commercially producing an aminoalcohol derivative (I) having a biphenyl group. Also disclosed are a biphenyloxyacetaldehyde derivative used therefor, a method for producing such a biphenyloxyacetaldehyde derivat...
|
|
WO/2006/121081A1 |
A process for producing high-purity acetonitrile having a low absorbance at a wavelength of 200 nm. It requires a reduced amount of energy for purification and the purification step is simple. It considerably diminishes the propionitrile...
|
|
WO/2006/119745A2 |
A method for the production of a,ß-unsaturated compounds of general formula (I) is disclosed, where R1 and R2 independently = H, substituted or unsubstituted alkyl or aryl, R3 = H, substituted or unsubstituted alkyl or aryl, or a functi...
|
|
WO/2006/120125A1 |
Provided herein are compounds of the formula (I), as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing...
|
|
WO/2006/121391A1 |
A compound of formula (I), or pharmaceutically acceptable salts thereof wherein X is selected from hydrogen, halo, -CN, -CON2, -CON(C1-6alkyl)H, -CON(C1-6alkyl)2 and heterocyclic groups; R1 is selected from C1-6alkyl and C3-6cycloalkyl; ...
|
|
WO/2006/120144A1 |
The invention relates to a method for isolating methyl glycine nitrile-N,N-diacetonitriles (MGDN) from an MGDN-containing aqueous emulsion with an MGDN content of 3 - 50% by weight in a crystallizer. The inventive method is characterized...
|
|
WO/2006/117791A1 |
The invention discloses novel dicyanostilbene derivatives bound to a methacrylic moiety that can serve as an active chromophore in a 3-dimensional optical memory, processes for its synthesis and its intermediates.
|
|
WO/2006/118955A2 |
Methods for preparing oxindole and thio-oxindole compounds are provided, which compounds are useful as precursors to useful pharmaceutical compounds. Specifically provided are methods for preparing 5-pyrrole-3,3-oxindole compounds and 5-...
|
|
WO/2006/115895A2 |
In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted or unsubstituted six membered heterocyclic ring that includes at least two nitrogen ato...
|
|
WO/2006/115033A1 |
Disclosed is a polymerizable compound (for example, a polymerizable compound represented by the formula [9] below) which is useful as a material for optical compensation films such as polarizing plates and retardation plates or optically...
|
|
WO/2006/115237A1 |
An industrially advantageous process for 4-amino-2-alkylthio-5-pyrimidinecarbaldehyde production by which a 4-amino-2-alkylthio-5-pyrimidinecarbaldehyde can be easily produced in a high yield; an intermediate compound for use in the proc...
|
|
WO/2006/115130A1 |
Calcium bis[(2S)-3-[3-(2S)-3-(4-chloro-2-cyanophenoxy)- 2-fluoropropoxy]phenyl]-2-isopropoxypropionate] of the formula (I).
|
|
WO/2006/111233A1 |
The invention relates to the use of compounds of formula (I), comprising radicals as defined in the description, which are used as antioxidants, corresponding novel compounds and preparations, in addition to a corresponding production me...
|
|
WO/2006/111234A1 |
The invention relates to the use of compounds which do not display any essential UV-absorption in the UV-A- or UV-B-ranges, but are reactive under conditions of application, in order to produce UV-A- or UV-B- protection during applicatio...
|
|
WO/2006/112073A1 |
A silicon-containing reagent for crosscoupling reactions which is an organosilicon compound having excellent stability, capable of crosscoupling reactions under mild reaction conditions without using a fluoride ion, transition-metal prom...
|
|
WO/2006/113552A2 |
The present invention relates to a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or a combination thereof; wherein R°, R1, R1', R2, R2'...
|
|
WO/2006/112338A1 |
This invention provides a phase plate suitable for use in a broadband, an optical element such as a polarizing diffractive element having an excellent diffraction efficiency, a polymerizable liquid crystal composition for use in them, an...
|
